Zobrazeno 1 - 10
of 23
pro vyhledávání: '"David Lyden"'
Autor:
Raghu P. Kataru, Babak J. Mehrara, Catherine L. Ly, Hyeung Ju Park, Sagrario Ortega, David Lyden, Jung Eun Baik, Jinyeon Shin, Sonia Rehal
Publikováno v:
Cancer Immunology Research. 7:1345-1358
Proliferation of aberrant, dysfunctional lymphatic vessels around solid tumors is a common histologic finding. Studies have shown that abnormalities in lymphatic function result in accumulation of inflammatory cells with an immunosuppressive profile.
Autor:
Marc Ladanyi, William D. Travis, Matthew J. Bott, David Lyden, Yuan Liu, Axel Martin, Nikolaus Schultz, Kay See Tan, Prasad S. Adusumilli, Michael F. Berger, Gregory J Riely, Francisco Sanchez-Vega, Gaetano Rocco, David R. Jones, Whitney S. Brandt, Jamie E. Chaft, Marcin Imielinski, Bob T. Li, Daniela Molena, Ronglai Shen, Bernard J. Park, Ariana Adamski, David B. Solit, Marty W. Mayo, Natasha Rekhtman, Gregory D. Jones, Jian Zhou, Hira Rizvi
Publikováno v:
JAMA Surg
IMPORTANCE: Recommendations for adjuvant therapy after surgical resection of lung adenocarcinoma (LUAD) are based solely on TNM classification but are agnostic to genomic and high-risk clinicopathologic factors. Creation of a prediction model that in
Autor:
Jane Zhang, Rachel Yanowitch, Yujie Huang, William S. Cobb, Jeffrey P. Greenfield, Prajwal Rajappa, Babacar Cisse, David J. Pisapia, Beiyi Shen, Jason T. Huse, Jacqueline Bromberg, David Lyden, Caitlin Hoffman, Kunal Garg, Timothy A. Chan, Sara Haddock, Laura Daly, Emma Vartanian
Publikováno v:
Clinical Cancer Research. 23:3109-3119
Purpose: While the tumor microenvironment has been known to play an integral role in tumor progression, the function of nonresident bone marrow–derived cells (BMDC) remains to be determined in neurologic tumors. Here we identified the contribution
Autor:
Mithat Gonen, Milica Tesic Mark, Ronald P. DeMatteo, Michael I. D’Angelica, Gokce Askan, T. Peter Kingham, Olca Basturk, Henrik Molina, Bruno Costa-Silva, Constantinos P. Zambirinis, Jonathan M. Hernandez, William R. Jarnagin, Linda Bojmar, David Lyden, Peter J. Allen, Elke J. A. H. van Beek, Alexandre Doussot, Jian Zheng
Background Exosomes are nanovesicles that have been shown to mediate carcinogenesis in pancreatic ductal adenocarcinoma (PDAC). Given the direct communication of pancreatic duct fluid with the tumor and its relative accessibility, we aimed to determi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::008f77154cb09a219404989d7ef9bd99
https://europepmc.org/articles/PMC6779041/
https://europepmc.org/articles/PMC6779041/
Autor:
Mario E. Lacouture, Eli L. Diamond, Benjamin H. Durham, Ryma Benayed, Pallavi Khattar, David Lyden, Ira J. Dunkel, Omar Abdel-Wahab, Ehud Lavi, Neerav Shukla, Sara Zarnegar
Publikováno v:
Pediatric Blood & Cancer. 65
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm characterized by constitutive activation of extracellular signal-regulated kinase (ERK). Genomic characterization has identified activating point mutations including mutually exc
Autor:
Erez Schori, Laura Daly, Larry Norton, Marc Ladanyi, Ninghui Mao, David B. Solit, Shu Hui Liu, Haiying Zhang, Luc G. T. Morris, William Pao, Katia Manova-Todorova, Robert Vogel, Grégoire Altan-Bonnet, Michael Zinda, Maria E. Arcila, Jacqueline Bromberg, Eirini Bournazou, Monica Red Brewer, David Lyden, Ross L. Levine, Qing Chang, Sizhi P. Gao, Dennis Huszar, Elisa de Stanchina, Tyler Chan
Publikováno v:
Science signaling. 9(421)
Lung adenocarcinomas with mutant epidermal growth factor receptor (EGFR) respond to EGFR-targeted tyrosine kinase inhibitors (TKIs), but resistance invariably occurs. We found that the Janus kinase (JAK)/signal transduction and activator of transcrip
Autor:
Iska Moxon-Emre, Livia Garzia, Karin M. Muraszko, Thomas Hielscher, Satoru Osuka, Xing Fan, Andrew S. Moore, Toshihiro Kumabe, Betty Luu, Cynthia Hawkins, Tibor Hortobágyi, David T.W. Jones, Leos Kren, Sridharan Gururangan, Peter Hauser, Peter B. Dirks, David Shih, Jeffrey R. Leonard, Andrey Korshunov, Michael K. Cooper, Gerald A. Grant, Naoki Kagawa, Andrew R. Hallahan, Claudia C. Faria, Pim J. French, Donald J. Mabbott, Joshua B. Rubin, Jaume Mora, Sarah Leary, Michael A. Grotzer, Cécile Faure-Conter, Stefan M. Pfister, Erwin G. Van Meir, Rajeev Vibhakar, Bognár László, Shin Jung, Yoon Jae Cho, Reid C. Thompson, Nada Jabado, Alexander G. Weil, David C.Y. Low, Karel Zitterbart, Enrique López-Aguilar, Alice Carvalho, Kenneth Tou En Chang, Ho Keung Ng, Ana Nikolic, Eric M. Thompson, Jennifer A. Chan, James T. Rutka, Kay Ka Wai Li, Yu Yao, Paul A. Northcott, Vijay Ramaswamy, Roger E. McLendon, Wan Tew Seow, Wendy J. Ingram, Wiesława Grajkowska, Ronald L. Hamilton, Marcel Kool, Caterina Giannini, William A. Weiss, Luca Massimi, Ian F. Pollack, Marie Lise C. van Veelen, Jaroslav Sterba, David Lyden, Ji Yeoun Lee, Ulrich Schüller, Sébastien Perreault, Nalin Gupta, Johan M. Kros, Arman Jahangiri, Roger J. Packer, Brandyn A. Castro, Lola B. Chambless, Jeffrey J. Olson, Seung-Ki Kim, Almos Klekner, Woo Youl Jang, Uri Tabori, Michelle Fèvre-Montange, Marc Remke, Takafumi Wataya, Michael D. Taylor, Sofia Nunes, Marta Perek-Polnik, Tímea Pócza, Amulya A. Nageswara Rao, James M. Drake, Tenzin Gayden, Alexandre Vasiljevic, Eric S. Lipp, Christian Schneider, Alvaro Lassaletta, Jennifer Adamski, Tarek Shalaby, Darell D. Bigner, Teiji Tominaga, Naoya Hashimoto, Anne Jouvet, Abhaya V. Kulkarni, Noriyuki Kijima, Tomoko Shofuda, José Pimentel, Eric Bouffet, Maria Luisa Garrè
Publikováno v:
Lancet Oncology, 17(4), 484-495. Lancet Publishing Group
LANCET ONCOLOGY
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
The Lancet. Oncology
LANCET ONCOLOGY
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
The Lancet. Oncology
BACKGROUND: Patients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called second-look surgeries, and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c87f10f27a6e147d048e5f59f46681a
Autor:
David Lyden, Stephen Gilheeney, Oren J. Becher, Suzanne L. Wolden, Mark M. Souweidane, Yasmin Khakoo, Amy Budnick, William R. Polkinghorn, Ira J. Dunkel
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 81:e15-e20
Purpose We previously reported excellent local control for treating medulloblastoma with a limited boost to the tumor bed. In order to decrease ototoxicity, we subsequently implemented a tumor-bed boost using intensity-modulated radiation therapy (IM
Autor:
David Lyden, Sofia Haque, Debra A. Goldman, Neeta Pandit-Taskar, Kevin D. De Braganca, Pat Zanzonico, Yasmin Khakoo, Jorge A. Carrasquillo, Serge K. Lyashchenko, Maria Donzelli, Ira J. Dunkel, Steven M. Larson, Kim Kramer, Mark M. Souweidane, Nai-Kong V. Cheung, John L. Humm, Stephen Gilheeney, Suzanne L. Wolden, Jason S. Lewis, Jeffrey P. Greenfield
Publikováno v:
Memorial Sloan Kettering Cancer Center
BACKGROUND: High-risk and recurrent medulloblastoma (MB) is associated with significant mortality. The murine monoclonal antibody 3F8 targets the cell-surface disialoganglioside GD2 on MB. We tested the efficacy, toxicity, and dosimetry of compartmen
Autor:
Thomas C. Lee, Ira J. Dunkel, Danielle Novetsky, David Lyden, Katherine L. Beaverson, Jonathan L. Finlay, David H. Abramson, Weiji Shi, Beryl McCormick
Publikováno v:
Pediatric Blood & Cancer. 49:643-648
Background Retinoblastoma patients with RB1 germline mutations are at risk of developing second malignancies and external beam radiation therapy increases the risk. Carboplatin-containing chemotherapy regimens in conjunction with local therapies have